Loading stock data…
Loading stock data…
US$0.06
Get one email when HEPA crosses your level. Checked every 15 minutes during market hours.
▲ +0.01 (9.91%)up today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
48.7
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
-0.00
Bearish momentumMACD below its signal line (-0.00).
50-day average
0.07
Price belowShort-term trend reference.
200-day average
0.06
Price belowLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapies for chronic liver diseases. Its key asset, Rencofilstat, is a potent cyclophilin inhibitor aimed at treating conditions such as non-alcoholic steatohepatitis (NASH), liver fibrosis, and hepatocellular carcinoma (HCC). Rencofilstat targets multiple molecular pathways involved in liver disease progression, from initial triggers to those impairing liver function. The company lever…
hepionpharma.com2 strong buy · 4 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2025-03-01)
2 strong buy · 4 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2025-02-01)
2 strong buy · 4 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2025-01-01)
2 strong buy · 4 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2024-12-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-07-16 | 1.1 | 1.17 | ✓ Beat |
| 2026-03-17 | 0.42 | 0.65 | ✓ Beat |
| 2026-03-04 | 0.06 | 0.15 | ✓ Beat |
| 2026-02-10 | 0.96 | 1 | ✓ Beat |
| 2024-04-16 | -131.5 | -81.23 | ✓ Beat |
| 2024-01-05 | -2.63 | -2.42 | ✓ Beat |
| 2023-11-19 | -3.12 | -2.74 | ✓ Beat |
Companies in the same industry, via Finnhub